期刊
CANCER JOURNAL
卷 15, 期 2, 页码 105-109出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/PPO.0b013e31819e31f2
关键词
-
类别
The intraperitoncal delivery of chemotherapy as a strategy to manage epithelial ovarian cancer has been extensively examined in both the preclinical and clinical settings. Several randomized phase 3 trials have documented improved survival associated with regional versus Systemic delivery of cisplatin in the primary chemotherapeutic management of small volume residual advanced ovarian cancer. Unfortunately, despite the existence of these evidence-based data, this management strategy remains underutilized. Future research efforts are mandated to develop regimens which improve the toxicity profile of this novel method of treatment while maintaining the documented enhanced efficacy of the approach.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据